Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Linifanib |
| Trade Name | |
| Synonyms | ABT-869|AL-39324 |
| Drug Descriptions |
Linifanib (ABT-869) is a receptor tyrosine kinase inhibitor with specificity against FLT1 (VEGFR1), CSF-1R, KDR (VEGFR2), FLT3, and KIT, which may result in inhibition of cell proliferation and tumor growth, and tumor regression (PMID: 16648571). |
| DrugClasses | CSF1R Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR-beta Inhibitor 14 VEGFR Inhibitor (Pan) 36 |
| CAS Registry Number | 796967-16-3 |
| NCIT ID | C71759 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + Linifanib + Paclitaxel | Carboplatin Linifanib Paclitaxel | 0 | 0 |
| Linifanib | Linifanib | 8 | 0 |